Venture Capital

Funding Roundup: IRX, Genesis, Inimex, VeraLight and ONCODESIGN

Busy day on the funding side today. Too many to keep up with and I’m pretty sure I missed a couple but, no time for whining:

• ONCODESIGN Secures 4.7M in Financing
• VeraLight secures $20 million series C financing for a non-invasive diabetes screening system
• IRX therapeutics completes $25 million series A preferred stock offering to continue clinical development of the phase II cancer drug, IRX-2 (citoplurikin), for head and neck cancers.
• Inimex raises $22 million to fund and IND and clinical trials for its antibiotic resistance drug.
• Genesis pharmaceuticals enterprises (China) closes $30 million private note placement to pay for the rights to manufacture a new Chinese drug for the heart called Ligustrazine Ferulic Acid Acetate, or LFAA for short.
• AxoGen is provided with $7.5 million venture loan to advance their peripheral nerve repair system, AVANCE.

Theoretically Related Posts

• July 7, 2008 -- Secretive Agios Makes Splash with $33M Series A (0)
• June 9, 2008 -- Drug Development: From Discovery to NDA (0)
• November 17, 2008 -- Zafgen Raises $14 Million in Series B (0)
• November 17, 2008 -- Pacira Pharmaceuticals Raises $85 Million in Series A (0)
• November 11, 2008 -- Accera Completes $35 Million Series C Financing (1)
• October 22, 2008 -- Neuroptix Raises $18.5 Million in Successful B Round (0)
• October 22, 2008 -- Apitope Raises EUR 10 Million in Series A Financing (0)
• September 8, 2008 -- Proteolix Raises $79M in Series C (0)
• August 25, 2008 -- Proteostasis Rakes in $45M in Series A (0)
• August 12, 2008 -- Heathcare / Medical Venture Capital Groups (0)

© 2008 Pharmababble.